Bb Biotech Ag Disclosed New Halozyme Therapeutics Inc Position

February 15, 2018 - By Kurt Siggers

 Bb Biotech Ag Disclosed New Halozyme Therapeutics Inc Position

Investors sentiment decreased to 1.26 in Q3 2017. Its down 0.76, from 2.02 in 2017Q2. It fall, as 14 investors sold Halozyme Therapeutics, Inc. shares while 44 reduced holdings. 18 funds opened positions while 55 raised stakes. 118.53 million shares or 0.58% less from 119.22 million shares in 2017Q2 were reported.

Fisher Asset Lc holds 583,221 shares or 0.01% of its portfolio. Moreover, Metropolitan Life Insur Company Ny has 0.01% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 79,604 shares. Proshare Advsrs Lc has 0.01% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). State Street Corp invested in 0.01% or 3.68M shares. Tower Limited Liability Corporation (Trc) holds 13,989 shares. Senzar Asset Management Lc reported 3.83M shares. Moreover, Federated Invsts Pa has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Hightower Advsrs Limited Company owns 23,430 shares or 0% of their US portfolio. Principal Group Incorporated Inc owns 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 16,941 shares. Dixon Hubard Feinour Brown Va reported 17,944 shares. Royal Comml Bank Of Canada holds 0% or 14,746 shares. Sg Americas Secs Limited Liability accumulated 28,081 shares. First Republic holds 0.01% or 42,000 shares in its portfolio. Voya Investment Limited Liability reported 53,034 shares or 0% of all its holdings. Fred Alger Mgmt reported 0.03% in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

The New Bb Biotech Ag Holding in Halozyme Therapeutics Inc

Bb Biotech Ag reported SC 13G/A form with the SEC for Halozyme Therapeutics Inc. Access it here: 000119312518045492. As reported by Bb Biotech Ag, the filler owns 6% or 8,520,137 shares of the Health Care–company.

Halozyme Therapeutics Inc stake is new for [reportingPerson]. Date of activity: December31, 2017. This shows Bb Biotech Ag’s positive view for Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc Institutional Sentiment

Filings show 167 investors own Halozyme Therapeutics Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 8810321. 105199434 were owned by these investors. 32 funds opened new Halozyme Therapeutics Inc stakes, 62 increased positions. There were 17 that closed positions and 49 reduced them.

2 investors had the stock in their top 10. Some are: Senzar Asset Management Llc, Third Security Llc, Msd Partners L.P., Bb Biotech Ag..

Third Security Llc is an investor bullish on Halozyme Therapeutics Inc, owning 19829337 shares as of Q3 2015 for 10.59% of its portfolio. Leisure Capital Management owns 24605 shares or 0.36% of its portfolio. CA First Republic Investment Management Inc have 0.01% of its portfolio for 43000 shares. Further, Franklin Street Advisors Inc reported stake worth 0.08% of its portfolio. The CA Doheny Asset Management owns 51415 shares. Halozyme Therapeutics Inc is 0.36% of its portfolio.

Business Profile

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

SEC Form 13G.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on February, 27. They expect $0.67 EPS, up 419.05 % or $0.88 from last year’s $-0.21 per share. HALO’s profit will be $94.51M for 6.97 P/E if the $0.67 EPS becomes a reality. After $0.02 actual EPS reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3,250.00 % EPS growth.

The stock increased 1.47% or $0.27 during the last trading session, reaching $18.68. About 331,646 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since February 15, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.64 billion. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It currently has negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Among 9 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Halozyme Therapeutics has $27 highest and $12 lowest target. $20.43’s average target is 9.37% above currents $18.68 stock price. Halozyme Therapeutics had 21 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, September 14 by Piper Jaffray. The stock has “Buy” rating by Canaccord Genuity on Wednesday, July 26. The firm earned “Market Outperform” rating on Tuesday, August 11 by JMP Securities. BMO Capital Markets maintained the stock with “Market Perform” rating in Wednesday, November 8 report. The rating was maintained by Deutsche Bank on Friday, September 15 with “Buy”. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The rating was maintained by Barclays Capital with “Overweight” on Wednesday, February 24. The stock has “Overweight” rating by Barclays Capital on Tuesday, September 22. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Buy” rating given on Wednesday, January 24 by Deutsche Bank. The firm has “Buy” rating given on Thursday, November 3 by Deutsche Bank.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: which released: “This News Explains Halozyme Therapeutics’ Double-Digit Drop Today” on January 17, 2018, also with their article: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Halozyme …” published on January 19, 2018, published: “Why Halozyme Went Down Yesterday?” on January 17, 2018. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: and their article: “Timpani Capital Management LLC Buys Mimecast, Alkermes PLC, Halozyme …” published on February 14, 2018 as well as‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: January 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.